Cover Image
市場調查報告書

腎臟癌治療藥市場 (Afinitor·Avastin·Inlyta·Nexavar·Proleukin·Sutent、Torisel·Votrient) :全球產業分析·開發平台分析·市場規模·市場佔有率·成長率·趨勢·預測

Kidney Cancer Drugs Market (Afinitor, Avastin, Inlyta, Nexavar, Proleukin, Sutent, Torisel, Votrient) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

出版商 Transparency Market Research 商品編碼 324591
出版日期 內容資訊 英文 82 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
腎臟癌治療藥市場 (Afinitor·Avastin·Inlyta·Nexavar·Proleukin·Sutent、Torisel·Votrient) :全球產業分析·開發平台分析·市場規模·市場佔有率·成長率·趨勢·預測 Kidney Cancer Drugs Market (Afinitor, Avastin, Inlyta, Nexavar, Proleukin, Sutent, Torisel, Votrient) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
出版日期: 2015年01月23日 內容資訊: 英文 82 Pages
簡介

本報告提供已上市的腎臟癌治療藥及開發平台藥物候補的市場相關調查,提供您市場背景,推動市場成長的要素與阻礙要素及市場機會分析,領導品牌的收益規模的變化與預測,開發平台後期的藥物候補收益規模預測,並彙整各地區的趨勢,建議,主要企業簡介等資訊。

第1章 序文

第2章 摘要整理

第3章 全球腎臟癌治療藥市場:概要

  • 市場動態·概要
  • 市場促進因素
  • 市場成長的阻礙要素
  • 市場機會
  • 活動影響分析
  • 法律體制
  • 市場魅力度分析:全球腎臟癌治療藥市場 (各地區)
  • 主要經營者的市場佔有率分析

第4章 全球腎臟癌治療藥市場:各主要品牌

  • 概要
    • 全球腎臟癌治療藥市場:各主要品牌的收益的變化與預測
  • Sutent (Sunitinib)
    • 市場收益的變化與預測
  • Nexavar (Sorafenib)
    • 市場收益的變化與預測
  • Afinitor (Everolimus)
    • 市場收益的變化與預測
  • Votrient (Pazopanib)
    • 市場收益的變化與預測
  • Inlyta (Axitinib)
    • 市場收益的變化與預測
  • Avastin (Bevacizumab)
    • 市場收益的變化與預測
  • Torisel (Temsirolimus)
    • 市場收益的變化與預測
  • Proleukin (Aldesleukin)
    • 市場收益的變化與預測

第5章 全球腎臟癌治療藥市場:開發平台分析

  • 概要
    • 按全球腎臟癌治療藥市場:開發平台藥物候補的收益的變化與預測
  • Opdivo (Nivolumab) (Bristol-Myers Squibb)
    • 市場收益的變化與預測
  • Keytruda (Anti PD 1) (Pembrolizumab) (Merck & Co., Inc.)
    • 市場收益的變化與預測
  • Cabozantinib (XL184) (Exelixis, Inc.)
    • 市場收益的變化與預測
  • AGS-003 (Argus Therapeutics, Inc.)
    • 市場收益的變化與預測
  • Dovitinib (TK1258) Novartis AG
    • 市場收益的變化與預測

第6章 全球腎臟癌治療藥市場:各地區

  • 概要
    • 全球腎臟癌治療藥市場:各地區的收益的變化與預測
  • 北美
    • 市場收益的變化與預測
  • 歐洲
    • 市場收益的變化與預測
  • 亞太地區
    • 市場收益的變化與預測
  • 其他地區
    • 市場收益的變化與預測

第7章 建議

第8章 企業簡介

  • Bayer AG
  • F. Hoffmann-La Roche, Ltd.
  • GlaxoSmithKline, plc
  • Novartis AG
  • Pfizer, Inc.
    • 企業概要
    • 財務概要
    • 產品系列
    • 產業策略
    • 近幾年的發展趨勢等

圖表一覽

目錄

Kidneys are among the most crucial organs of the human body. Their role in regulating blood pressure and serving homeostatic functions is critical in maintaining the balance of nutrients and toxins in the body. Kidneys serve as natural blood filters, removing the water-soluble wastes and reabsorbing the essential elements from the blood. Since they play such a crucial role, kidneys require constant regeneration of dead nephrons and proper blood circulation to maintain healthy cell growth, due to which, they are susceptible to metastasis and cancerous tumors. Renal cell carcinoma, the most common type of kidney cancer, is among the toughest cancers to treat, especially in the advanced stages. Until 1980's, the treatment of kidney cancer included surgical removal of the kidneys. The treatment later progressed to laparoscopic removal of the tumor-affected part of the kidneys, significantly increasing the survival rate and patient comfort. Drugs are usually given to stage four advanced renal cell carcinoma patients with disease progression. Various forms of cancer treatment mechanism have been implemented among the presently approved drugs for kidney cancer; these include, VEGF (Vascular Endothelial Growth Factor) inhibitor, angiogenesis inhibitor, cytokine therapy, and immune modulation therapy to name a few.

This research report provides a detailed analysis of the global kidney cancer drugs market and helps in understanding the various driving factors of this market. The market overview section provides analysis of the market dynamics and trends such as drivers, restraints, and opportunities that influence the current nature of the market. The section also forecasts the future scenario of the market. The executive summary gives detailed insights about the report and the market in general. It also contains a market snapshot, which provides a glimpse into the current scenario of the global kidney cancer drugs market. Event impact analysis and other market dynamics tools such as market attractiveness analysis, regulatory framework analysis, and market share analysis have also been explained in the market overview section of the report, in order to deliver a thorough analysis of the overall competitive scenario in the global kidney cancer drugs market.

The global kidney cancer drugs market is segmented on the basis of major branded drugs produced and geography. By major branded drugs, the market is further segmented into the major brands approved for the indication of renal cell carcinoma such as Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin/Interleukin-2), Sutent (Sunitinib), Torisel (Temsirolimus), and Votrient (Pazopanib). The report also includes pipeline analysis of the most potential drugs, which are currently in phase 2 and phase 3 trials for renal cell carcinoma indication. Considering 2013 as the base year for estimating the market size and 2012 as the historical year, the market size estimations for the period from 2012 to 2020 have been provided for each of the major branded drugs mentioned above in terms of USD million. The CAGR (%) of each market segment for the forecast period between 2012 to 2016 and 2016 to 2020 has also been provided along with market size estimations.

Geographically, the global kidney cancer drugs market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of World (RoW), Russia being included in the RoW region. The market size estimations for the period between 2012 and 2020 and market forecast for the period 2014 - 2020 have been provided for each of these regions by revenue in terms of USD million along with the CAGR for the forecast period 2014 to 2020. This study further offers market recommendations for market players of the global kidney cancer drugs market, which include factors that may play a critical role in enhancing or boosting the market share of companies in the near future. The report also advices measures that need to be considered to achieve success for kidney cancer drug manufacturers and marketers globally.

The report concludes with company profiles, which include key information about the major players actively participating in the kidney cancer drugs market. The report profiles the market players in terms of company overview, financial overview, business strategy, recent developments, and product portfolio. The companies featured in this report have exclusive patent rights to the following major branded drugs: Novartis AG., F. Hoffman-La Roche., Pfizer, Inc., Bayer Pharma AG., and GlaxoSmithKline, plc.

The global kidney cancer drugs market is segmented as follows:

Kidney Cancer Drugs Market, by Major Branded Drugs

  • Sutent (Sunitinib)
  • Nexavar (Sorafenib)
  • Afinitor (Everolimus)
  • Votrient (Pazopanib)
  • Inlyta (Axitinib)
  • Avastin (Bevacizumab)
  • Torisel (Temsirolimus)
  • Proleukin (Aldesleukin)

Kidney Cancer Drugs Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW)

Table of Contents

Chapter 1 Introduction

  • 1.1 Report Description
  • 1.2 Market Segmentation
  • 1.3 Research Methodology
  • 1.4 Assumptions

Chapter 2 Executive Summary

  • 2.1 Market Snapshot: Global Kidney Cancer Drugs Market
  • 2.2 Comparative Analysis: Global Kidney Cancer Drugs Market, By Geography, 2013 and 2020 (Value %)

Chapter 3 Global Kidney Cancer Drugs Market Overview

  • 3.1 Market Dynamics and Overview
  • 3.2 Market Drivers
    • 3.2.1 Rising Incidence of Kidney Cancer Expected to Boost Market Growth
    • 3.2.2 Increasing Geriatric Population Likely to Fuel the Growth of Kidney Cancer Drugs Market
      • 3.2.2.1.1 Global Percentage Change in the World's Population by Age: 2010-2050
    • 3.2.3 Approval of Novel Molecules is Expected to Drive Market Growth
  • 3.3 Market Restraints
    • 3.3.1 High Prices of Branded Cancer Drugs might Impede the Growth of the Market
    • 3.3.2 Increasing Preference for Generic Drug Variants might Negatively Influence the Market Growth
  • 3.4 Market Opportunities
    • 3.4.1 Focusing on Emerging Markets
  • 3.5 Event Impact Analysis
  • 3.6 Regulatory Framework
  • 3.7 Market Attractiveness Analysis: Global Kidney Cancer Drugs Market, by Geography
  • 3.8 Market Share Analysis: Global Kidney Cancer Drugs Market, by Key Players, 2013 (Value %)

Chapter 4 Global Kidney Cancer Drugs Market, by Major Branded Drugs

  • 4.1 Overview
    • 4.1.1 Global Kidney Cancer Drugs Market Revenue, by Major Branded Drugs, 2012 - 2020 (USD Million)
  • 4.2 Sutent (Sunitinib)
    • 4.2.1 Global Sutent (Sunitinib) Market Revenue, 2012 - 2020 (USD Million)
  • 4.3 Nexavar (Sorafenib)
    • 4.3.1 Global Nexavar (Sorafenib) Market Revenue, 2012 - 2020 (USD Million)
  • 4.4 Afinitor (Everolimus)
    • 4.4.1 Global Afinitor (Everolimus) Market Revenue, 2012 - 2020 (USD Million)
  • 4.5 Votrient (Pazopanib)
    • 4.5.1 Global Votrient (Pazopanib) Market Revenue, 2012 - 2020 (USD Million)
  • 4.6 Inlyta (Axitinib)
    • 4.6.1 Global Inlyta (Axitinib) Market Revenue, 2012 - 2020 (USD Million)
  • 4.7 Avastin (Bevacizumab)
    • 4.7.1 Global Avastin (Bevacizumab) Market Revenue, 2012 - 2020 (USD Million)
  • 4.8 Torisel (Temsirolimus)
    • 4.8.1 Global Torisel (Temsirolimus) Market Revenue, 2012 - 2020 (USD Million)
  • 4.9 Proleukin (Aldesleukin)
    • 4.9.1 Global Proleukin (Aldesleukin) Market Revenue, 2012 - 2020 (USD Million)

Chapter 5 Global Kidney Cancer Drugs Market, Pipeline Analysis

  • 5.1 Overview
    • 5.1.1 Global Kidney Cancer Drugs Market Revenue, by Pipeline Drugs, 2015 - 2020 (USD Million)
  • 5.2 Opdivo (Nivolumab) (Bristol-Myers Squibb)
    • 5.2.1 Global Opdivo Market Revenue, 2015 - 2020 (USD Million)
  • 5.3 Keytruda (Anti PD 1) (Pembrolizumab) (Merck & Co., Inc.)
    • 5.3.1 Global Keytruda Market Revenue, 2015 - 2020 (USD Million)
  • 5.4 Cabozantinib (XL184) (Exelixis, Inc.)
    • 5.4.1 Global Cabozantinib Market Revenue, 2017 - 2020 (USD Million)
  • 5.5 AGS-003 (Argus Therapeutics, Inc.)
    • 5.5.1 Global AGS-003 Market Revenue, 2017 - 2020 (USD Million)
  • 5.6 Dovitinib (TK1258) [Novartis AG]
    • 5.6.1 Global Dovitinib Market Revenue, 2018 - 2020 (USD Million)

Chapter 6 Global Kidney Cancer Drugs Market, by Geography

  • 6.1 Overview
    • 6.1.1 Global Kidney Cancer Drugs Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • 6.2 North America
    • 6.2.1 North America Kidney Cancer Drugs Market Revenue, 2012-2020 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
  • 6.5 Rest of the World (RoW)
    • 6.5.1 Rest of the World Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)

Chapter 7 Recommendations

Chapter 8 Company Profiles

  • 8.1 Bayer AG
    • 8.1.1 Company Overview
    • 8.1.2 Financial Overview
    • 8.1.3 Product Portfolio
    • 8.1.4 Business Strategy
    • 8.1.5 Recent Developments
  • 8.2 F. Hoffmann-La Roche, Ltd.
    • 8.2.1 Company Overview
    • 8.2.2 Financial Overview
    • 8.2.3 Product Portfolio
    • 8.2.4 Business Strategy
    • 8.2.5 Recent Developments
  • 8.3 GlaxoSmithKline, plc
    • 8.3.1 Company Overview
    • 8.3.2 Financial Overview
    • 8.3.3 Product Portfolio
    • 8.3.4 Business Strategy
    • 8.3.5 Recent Developments
  • 8.4 Novartis AG
    • 8.4.1 Company Overview
    • 8.4.2 Financial Overview
    • 8.4.3 Product Portfolio
    • 8.4.4 Business Strategy
    • 8.4.5 Recent Developments
  • 8.5 Pfizer, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Overview
    • 8.5.3 Product Portfolio
    • 8.5.4 Business Strategy
    • 8.5.5 Recent Developments

List of Figures

  • FIG. 1 Kidney Cancer Drugs: Market Segmentation
  • FIG. 2 Global Kidney Cancer Drugs Market, by Major Branded Drugs, 2013 (USD Million)
  • FIG. 3 Global Kidney Cancer Pipeline Drugs Market (USD Million)
  • FIG. 4 Comparative Analysis: Global Kidney Cancer Drugs Market, by Geography, 2013 and 2020 (Value %)
  • FIG. 5 Kidney Cancer Drugs Market, Drivers and Restraints
  • FIG. 6 Global Percentage Change in the World's Population by Age: 2010 - 2050
  • FIG. 7 Major Developments in Kidney Cancer Drugs Market
  • FIG. 8 Market Attractiveness Analysis: Global Kidney Cancer Drugs Market, by Geography
  • FIG. 9 Market Share Analysis: Global Kidney Cancer Drugs Market, by Key Players, 2013 (Value %)
  • FIG. 10 Global Sutent (Sunitinib) Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 11 Global Nexavar (Sorafenib) Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 12 Global Afinitor (Everolimus) Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 13 Global Votrient (Pazopanib) Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 14 Global Inlyta (Axitinib) Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 15 Global Avastin (Bevacizumab) Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 16 Global Torisel (Temsirolimus) Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 17 Global Proleukin (Aldesleukin) Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 18 Global Opdivo Market Revenue, 2015 - 2020 (USD Million)
  • FIG. 19 Global Keytruda Market Revenue, 2015 - 2020 (USD Million)
  • FIG. 20 Global Cabozantinib Market Revenue, 2017 - 2020 (USD Million)
  • FIG. 21 Global AGS-003 Market Revenue, 2017 - 2020 (USD Million)
  • FIG. 22 Global Dovitinib Market Revenue, 2018 - 2020 (USD Million)
  • FIG. 23 North America Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 24 Europe Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 25 Asia Pacific Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 26 Rest of the World Kidney Cancer Drugs Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 27 Bayer AG: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 28 F. Hoffmann-La Roche, Ltd.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 29 GlaxoSmithKline, plc.: Annual Revenue, 2011 - 2013 (USD Million)
  • FIG. 30 Annual Revenue: Novartis AG 2011 - 2013 (USD Million)
  • FIG. 31 Pfizer, Inc.: Annual Revenue, 2011 - 2013 (USD Million)

List of Tables

  • TABLE 1 Market Snapshot: Global Kidney Cancer Market
  • TABLE 2 Stages of RCC, According to the U.S. TNM Classification
  • TABLE 3 Global Kidney Cancer Drugs Market Revenue, by Major Branded Drugs, 2012 - 2020 (USD Million)
  • TABLE 4 Global Kidney Cancer Drugs Market Revenue, by Pipeline Drugs, 2015 - 2020 (USD Million)
  • TABLE 5 Global Kidney Cancer Drugs Market Revenue, by Geography, 2012 - 2020 (USD Million)
Back to Top